Obesity and cardiovascular physiology: Impact of some pharmacological agents

Current Vascular Pharmacology

Volumn 3, Issue 2, 2005, Pages 185-193

  Chaput, Jean Philippe ^a   Bérubé Parent, Sonia ^a   Tremblay, Angelo ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Blood pressure; Drugs; Fat; Heart rate; Orlistat; Overweight; Pharmacotherapy; Sibutramine

Indexed keywords

ADRENALIN; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CERULENIN; DEXAMPHETAMINE; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENFLURAMINE; FLUOXETINE; GALANIN; GHRELIN; LIPOPROTEIN; MONOAMINE OXIDASE INHIBITOR; MULTIVITAMIN; NORADRENALIN; OREXIN A; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; RIMONABANT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; BEHAVIOR MODIFICATION; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EUPHORIA; EXERCISE; FECES INCONTINENCE; FLATULENCE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; IMMOBILIZATION; INSOMNIA; KIDNEY DISEASE; LIFESTYLE; MENTAL DISEASE; NERVOUSNESS; NONHUMAN; OBESITY; OSTEOARTHRITIS; OVERNUTRITION; PREVALENCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; SKINFOLD THICKNESS; TACHYCARDIA; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CLINICAL TRIALS; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; PIPERIDINES; PYRAZOLES; RISK FACTORS;

EID: 18044373422     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161053586886     Document Type: Review

References (58)

1. World Health Organization, Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic, World Health Organization, Geneva, 1998.
2. 8 Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - the Evidence Report. National Institutes of Health. Obes Res 6 (Suppl 2): 51S-209S.
3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-600.
4. Kopelman PG, Grace C. New thoughts on managing obesity. Gut 2004; 53: 1044-53.
5. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097-105.
6. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-6.
7. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-18.
8. Luque M, Garcia-Robles R, Tamargo J, Ruilope LM. Blood pressure control in hospital located hypertension units. Hypertension 2001; 37: 1030 (abstract).
9. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Inter Med 1997; 157: 2413-46.
10. Guidelines Subcommittee, World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
11. Kambham N, Markowitz J, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-509.
12. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health service use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-72.
13. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
14. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-7.
15. Van Gaal LF, Wauters M, DeLeeuw I. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21(Suppl 1): S5-9.
16. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657-67.
17. Jeffery RW. Weight management and hypertension. Ann Behav Med 1991; 13: 18-22.
18. Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 2003; 88: 2462-9.
19. NIH, National Heart Lung and Blood Institute, North American Association for the Study of Obesity. The practical guide. Identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: NIH; NIH publication 2000: 1-4084.
20. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 2004; 89: 2616-21.
21. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.
22. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1-11.
23. Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998; 22(Suppl 1): S30-5.
24. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23: 1016-24.
25. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 2003; 32: 1005-24.
26. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437-46.
27. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelley F, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363-9.
28. Schuh LM, Schuster CR, Hopper JA, Mendel CM. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology 2000; 147: 339-46.
29. Bérubé-Parent S, Prud'homme D, St-Pierre S, Doucet E, Tremblay A. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes 2001; 25: 1144-53.
30. Wynne RD, Brown T, Braybrooke RM, Jones S, Stott DA, Thornton GM. An evaluation of the cardiovascular effects of sibutramine in normal volunteers. Int J Obes 1995; 19: 144.
31. Stevens VJ, Obarzanek E, Cook NR, Lee I-M, Appel LJ, Smith West D, et al. Trials of Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 2001; 134: 1-11.
32. Mikhail N, Golub Ms, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42: 39-58.
33. McMahon RG, Fujioka K, Singh BN, Mendel CM, Rowe E, Kolston K, et al. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension. Arch Intern Med 2000; 160: 2185-91.
34. Halpern A, Mancini MC. Treatments of obesity: an update on anti-obesity medications. Obes Res 2003; 4: 25-42.
35. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-8.
36. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al. Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-87.
37. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor glucose control. Diabetes Care 2001; 24: 1957-60.
38. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. J Hum Hypertens 2002; 16: 13-9.
39. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11.
40. Tremblay A, Doucet E. Obesity: a disease or a biological adaptation? Obes Res 2000; 1: 27-35.
41. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes 1995; 19 (Suppl 7): S2-7.
42. Plourde G, Rousseau-Migneron S, Nadeau A. Effect of endurance training on beta-adrenergic system in three different skeletal muscles. J Appl Physiol 1993; 74: 164-6.
43. Plourde G, Rousseau-Migneron S, Nadeau A. β-Adrenoceptor adenylate cyclase system adaptation to physical training in rat ventricular tissue. J Appl Physiol 1991; 70: 1633-8.
44. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998; 22: 32-8.
45. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-98.
46. Doucet E, Imbeault P, Alméras N, Tremblay A. Physical activity and low-fat diet: is it enough to maintain weight stability in the reduced-obese individual following weight loss by drug therapy and energy restriction? Obes Res 1999; 7: 323-33.
47. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8: 431-7.
48. Reaven G, Karen S, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87: 827-31.
49. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-42.
50. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013-7.
51. 9-THC. Physiol Behav 1998; 65: 343-6.
52. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988; 11: 1-14.
53. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
54. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
55. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998; 63: PL113-7.
56. 1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462: 125-32.
57. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-53.
58. 1 receptors and obesity. Symposium on the Cannabinoids, El Escorial, Spain 2001: 101.